Prestige Invests $152m To Build Landmark R&D Center In South Korea
Singapore-Based Firm Conducted Korean IPO Earlier In 2021
Prestige BioPharma has announced a memorandum of understanding with the city of Busan, in South Korea, to build a 45,000 sq m R&D center, including to “accelerate the development of innovative antibody drugs.”
You may also be interested in...
Prestige Plans ‘Strong Price Competitiveness’ For Its Adalimumab Biosimilar
As Prestige BioPharma announced plans for Phase I and Phase III trials of its PBP1502 proposed adalimumab biosimilar, as well as expected filing dates in the EU and US, the company outlined how it believes its proprietary technology will allow its Humira rival to compete aggressively on price.
Prestige And Pharmapark Add Bevacizumab To Russia Collaboration
Russia’s Pharmapark has added Prestige BioPharma’s HD204 biosimilar bevacizumab product to the firms’ commercialization partnership, two years after kicking off the partnership with trastuzumab.
Mundipharma Strikes Deal For Prestige's Trastuzumab
Mundipharma has struck a deal with Prestige BioPharma for rights to the Singapore-based firm’s biosimilar trastuzumab in selected European markets.